Durect Corp (FRA:DC8A)
€ 0.785 -0.015 (-1.88%) Market Cap: 25.87 Mil Enterprise Value: 29.05 Mil PE Ratio: 0 PB Ratio: 22.56 GF Score: 60/100

Q2 2021 DURECT Corp Earnings Call Transcript

Jul 29, 2021 / 08:30PM GMT
Release Date Price: €11.8 (+2.61%)
Michael H. Arenberg
DURECT Corporation - CFO & Secretary

Good afternoon, and welcome to our Second Quarter 2021 Earnings Conference Call. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation.

I will provide a brief review of our financial results, and then Jim Brown, our President and CEO, will provide an update on our programs. We will then open up the call for a question-and-answer session.

Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT's products and developments, expected product benefits, our development plans, future clinical trials or projected financial results. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings, including our 10-K and 10-Qs under the heading Risk Factors. Let me now turn to our financials.

Total revenue in Q2 2021 was $2.3

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot